Immunization with murine breast cancer cells treated with antisense oligodeoxynucleotides to type I insulin-like growth factor receptor induced an antitumoral effect mediated by a CD8+ response involving Fas/Fas ligand cytotoxic pathway

Journal of Immunology

Volumn 176, Issue 6, 2006, Pages 3426-3437

  Schillaci, Roxana ^a   Salatino, Mariana ^a   Cassataro, Juliana ^b   Proietti, Cecilia J ^a   Giambartolomei, Guillermo H ^b   Rivas, Martín A ^a   Carnevale, Romina P ^a   Charreau, Eduardo H ^a   Elizalde, Patricia V ^a  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CD86 ANTIGEN; FAS LIGAND; HEAT SHOCK PROTEIN 70; SOMATOMEDIN C RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER IMMUNIZATION; CANCER INHIBITION; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; IMMUNE RESPONSE; MOUSE; MOUSE STRAIN; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SPLEEN CELL;

EID: 33644838002     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.6.3426     Document Type: Article

References (56)

1. Schadendorf, D., A. Paschen, and Y. Sun. 2000. Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma. Immunol Lett. 74: 67-74.
2. Dols, A., S. L. Meijer, J. W. Smith, II, B. A. Fox, and W. J. Urba. 2003. Allogeneic breast cancer cell vaccines. Clin. Breast Cancer 3(Suppl. 4): S173-S180.
3. Pardoll, D. M. 1995. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13: 399-415.
4. Mocellin, S., S. Mandruzzato, V. Bronte, M. Lise, and D. Nitti. 2004. Part I: vaccines for solid tumours. Lancet Oncol. 5: 681-689.
5. Sondak, V. K., and J. A. Sosman. 2003. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: melacine. Semin. Cancer Biol. 13: 409-415.
6. Staveley-O'Carroll, K., E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky. 1998. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95: 1178-1183.
7. + cytolytic T lymphocytes. J. Exp. Med. 183: 791-800.
8. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90: 3539-3543.
9. Chen, L. 1998. Immunological ignorance of silent antigens as an explanation of tumor evasion. Immunol. Today 19: 27-30.
10. Grabbe, S., S. Beissert, T. Schwarz, and R. D. Granstein. 1995. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol. Today 16: 117-121.
11. Galvin, F., G. J. Freeman, Z. Razi-Wolf, W. Hall, Jr., B. Benacerraf, L. Nadler, and H. Reiser. 1992. Murine B7 antigen provides a sufficient costimulatory signal for antigen-specific and MHC-restricted T cell activation. J. Immunol. 149: 3802-3808.
12. Antonia, S. J., T. Munoz-Antonia, G. Soldevila, J. Miller, and R. A. Flavell. 1995. B7-1 expression by a non-antigen presenting cell-derived tumor. Cancer Res. 55: 2253-2256.
13. Wallich, R., N. Bulbuc, G. J. Hammerling, S. Katzav, S. Segal, and M. Feldman. 1985. Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 315: 301-305.
14. Schwartz, R. H. 1992. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71: 1065-1068.
15. + T cells by B7-transfected melanoma cells. Science 259: 368-370.
16. Hui, K., F. Grosveld, and H. Festenstein. 1984. Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature 311: 750-752.
17. Goetsch, L., A. Gonzalez, O. Leger, A. Beck, P. J. Pauwels, J. F. Haeuw, and N. Corvaia. 2005. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int. J. Cancer 113: 316-328.
18. Mitsiades, C. S., N. S. Mitsiades, C. J. McMullan, V. Poulaki, R. Shringarpure, M. Akiyama, T. Hideshima, D. Chauhan, M. Joseph, T. A. Libermann, et al. 2004. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5: 221-230.
19. Balana, M. E., L. Labriola, M. Salatino, F. Movsichoff, G. Peters, E. H. Charreau, and P. V. Elizalde. 2001. Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells. Oncogene 20: 34-47.
20. Baserga, R., K. Reiss, H. Alder, Z. Pietrzkowski, and E. Surmacz. 1992. Inhibition of cell cycle progression by antisense oligodeoxynucleotides. Ann. NY Acad. Sci. 660: 64-69.
21. Salatino, M., R. Schillaci, C. J. Proietti, R. Carnevale, I. Frahm, A. A. Molinolo, A. Iribarren, E. H. Charreau, and P. V. Elizalde. 2004. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity. Oncogene 23: 5161-5174.
22. Lanari, C., A. A. Molinolo, and C. D. Pasqualini. 1986. Induction of mammary adenocarcinomas by medroxyprogesterone acetate in BALB/c female mice. Cancer Lett. 33: 215-223.
23. Sell, C., M. Rubini, R. Rubin, J. P. Liu, A. Efstratiadis, and R. Baserga. 1993. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc. Natl. Acad. Sci. USA 90: 11217-11221.
24. Resnicoff, M., W. Li, S. Basak, D. Herlyn, R. Baserga, and R. Rubin. 1996. Inhibition of rat C6 glioblastoma tumor growth by expression of insulin-like growth factor I receptor antisense mRNA. Cancer Immunol. Immunother. 42: 64-68.
25. Resnicoff, M., C. Sell, M. Rubini, D. Coppola, D. Ambrose, R. Baserga, and R. Rubin. 1994. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res. 54: 2218-2222.
26. Liu, X., T. Turbyville, A. Fritz, and L. Whitesell. 1998. Inhibition of insulin-like growth factor I receptor expression in neuroblastoma cells induces the regression of established tumors in mice. Cancer Res. 58: 5432-5438.
27. Resnicoff, M., J. Tjuvajev, H. L. Rotman, D. Abraham, M. Curtis, R. Aiken, and R. Baserga. 1996. Regression of C6 rat brain tumors by cells expressing an antisense insulin-like growth factor I receptor RNA. J. Exp. Ther. Oncol. 1: 385-389.
28. Trojan, J., T. R. Johnson, S. D. Rudin, J. Ilan, M. L. Tykocinski, and J. Ilan. 1993. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 259: 94-97.
29. Trojan, J., B. K. Blossey, T. R. Johnson, S. D. Rudin, M. Tykocinski, J. Ilan, and J. Ilan. 1992. Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. Proc. Natl. Acad. Sci. USA 89: 4874-4878.
30. Elizalde, P. V., C. Lanari, A. A. Molinolo, F. K. Guerra, M. E. Balana, M. Simian, A. M. Iribarren, and E. H. Charreau. 1998. Involvement of insulin-like growth factors-I and -II and their receptors in medroxyprogesterone acetate-induced growth of mouse mammary adenocarcinomas. J. Steroid Biochem. Mol. Biol. 67: 305-317.
31. Lanari, C., E. Kordon, A. Molinolo, C. D. Pasqualini, and E. H. Charreau. 1989. Mammary adenocarcinomas induced by medroxyprogesterone acetate: hormone dependence and EGF receptors of BALB/c in vivo sublines. Int. J. Cancer 43: 845-850.
32. Bal de Kier, J. E., L. Puricelli, and E. S. de Lustig. 1986. Modified adhesion behavior after in vitro passage of two related murine mammary adenocarcinomas with different metastasizing ability. Invasion Metastasis 6: 302-312.
33. Resnicoff, M., D. Coppola, C. Sell, R. Rubin, S. Ferrone, and R. Baserga. 1994. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res. 54: 4848-4850.
34. Machen, J., J. Harnaha, R. Lakomy, A. Styche, M. Trucco, and N. Giannoukakis. 2004. Antisense oligonucleotides down-regulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells. J. Immunol. 173: 4331-4341.
35. Robertson, J. D., K. Datta, S. S. Biswal, and J. P. Kehrer. 1999. Heat-shock protein 70 antisense oligomers enhance proteasome inhibitor-induced apoptosis. Biochem. J. 344(Pt. 2): 477-485.
36. Rohlik, Q. T., D. Adams, F. C. Kull, Jr., and S. Jacobs. 1987. An antibody to the receptor for insulin-like growth factor I inhibits the growth of MCF-7 cells in tissue culture. Biochem. Biophys. Res. Commun. 149: 276-281.
37. Proietti, C., M. Salatino, C. Rosemblit, R. Carnevale, A. Pecci, A. R. Kornblihtt, A. A. Molinolo, I. Frahm, E. H. Charreau, R. Schillaci, and P. V. Elizalde. 2005. Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells. Mol. Cell. Biol. 25: 4826-4840.
38. Vermes, I., C. Haanen, H. Steffens-Nakken, and C. Reutelingsperger. 1995. A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J. Immunol. Methods 184: 39-51.
39. Luini, W., D. Boraschi, S. Alberti, A. Aleotti, and A. Tagliabue. 1981. Morphological characterization of a cell population responsible for natural killer activity. Immunology 43: 663-668.
40. Kataoka, T., N. Shinohara, H. Takayama, K. Takaku, S. Kondo, S. Yonehara, and K. Nagai. 1996. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J. Immunol. 156: 3678-3686.
41. Melcher, A., S. Todryk, N. Hardwick, M. Ford, M. Jacobson, and R. G. Vile. 1998. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med. 4: 581-587.
42. Andrews, D. W., M. Resnicoff, A. E. Flanders, L. Kenyon, M. Curtis, G. Merli, R. Baserga, G. Iliakis, and R. D. Aiken. 2001. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J. Clin. Oncol. 19: 2189-2200.
43. Lowin, B., M. Hahne, C. Mattmann, and J. Tschopp. 1994. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 370: 650-652.
44. + T cell-mediated cytotoxicity. J. Immunol. 152: 1127-1133.
45. + cytotoxic T cells. Proc. Natl. Acad. Sci. USA 91: 4185-4189.
46. Simon, M. M., P. Waring, M. Lobigs, A. Nil, T. Tran, R. T. Hla, S. Chin, and A. Mullbacher. 2000. Cytotoxic T cells specifically induce Fas on target cells, thereby facilitating exocytosis-independent induction of apoptosis. J. Immunol. 165: 3663-3672.
47. + cytotoxic T lymphocytes and natural killer cells: participation of Fas ligand in granule exocytosis model of cytotoxicity. Biochem. Biophys. Res. Commun. 296: 328-336.
48. + cytotoxic T lymphocyte attack. Cancer Immunol. Immunother. 49: 193-207.
49. Carter, L. L., and R. W. Dutton. 1996. Type 1 and type 2: a fundamental dichotomy for all T-cell subsets. Curr. Opin. Immunol. 8: 336-342.
50. + T cells secreting Th1 or Th2 cytokines. Immunity 2: 271-279,
51. Baskar, S., S. Ostrand-Rosenberg, N. Nabavi, L. M. Nadler, G. J. Freeman, and L. H. Glimcher. 1993. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. USA 90: 5687-5690.
52. Trojan, J., H. T. Duc, L. C. Upegui-Gonzalez, F. Hor, Y. Guo, D. Anthony, and J. Ilan. 1996. Presence of MHC-1 and B-7 molecules in rat and human glioma cells expressing antisense IGF-I mRNA. Neurosci. Lett. 212: 9-12.
53. Srivastava, P. 2002. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu. Rev. Immunol. 20: 395-425.
54. Udono, H., and P. K. Srivastava. 1994. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J. Immunol. 152: 5398-5403.
55. Castellino, F., P. E. Boucher, K. Eichelberg, M. Mayhew, J. E. Rothman, A. N. Houghton, and R. N. Germain. 2000. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J. Exp. Med. 191: 1957-1964.
56. Scheffer, S. R., H. Nave, F. Korangy, K. Schlote, R. Pabst, E. M. Jaffee, M. P. Manns, and T. F. Greten. 2003. Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int. J. Cancer 103: 205-211.